Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > AMAG Pharmaceuticals, Inc. Announces Addition of Joseph V. Bonventre, M.D., Ph. D. to Board of Directors

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today announced the appointment of Joseph V. Bonventre, M.D., Ph.D. to the Company's Board of Directors.

AMAG Pharmaceuticals, Inc. Announces Addition of Joseph V. Bonventre, M.D., Ph. D. to Board of Directors

Cambridge, MA | Posted on February 27th, 2008

Dr. Bonventre holds appointments as the Robert H. Ebert Professor of Medicine at Harvard Medical School, in Cambridge, MA, and Professor of Health Sciences and Technology at Massachusetts Institute of Technology (MIT). He is Director of the Renal Division at Brigham & Women's Hospital in Boston, MA. Dr. Bonventre is a member of the Council of the American Society of Nephrology (ASN). He is Chair of the Kidney Group of the Harvard Stem Cell Initiative, co-chair of the Stem Cell, Regenerative Medicine and Tissue Engineering Center of the Brigham and Women's Hospital Research Institute and co-chair of the Technology in Medicine Initiative at the Brigham and Women's Hospital.

"We are delighted to have Dr. Bonventre join our Board at this important time for the Company. His academic experience, participation on scientific and medical advisory boards of several companies and his long-standing involvement with the ASN further strengthens our organization," commented Brian J.G. Pereira, M.D., President and Chief Executive Officer of AMAG Pharmaceuticals, Inc. "We look forward to Dr. Bonventre's contributions and welcome him to the Board," concluded Dr. Pereira.

Prior to his current appointments at Harvard Medical School and MIT, Dr. Bonventre served as Co-Director, Harvard-MIT Division of Health Sciences and Technology. In addition to his B.S. with distinction in Engineering Physics from Cornell University, Dr. Bonventre holds M.D. and Ph.D. degrees in Biophysics from Harvard University. He has honorary doctorate degrees from Mt. Saint Mary's College and from the Norwegian Institute of Science and Technology. Dr. Bonventre completed his internship and residencies in Medicine at Massachusetts General Hospital. He is published widely on kidney injury and repair.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration in December 2007 which was accepted for filing in February 2008.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Kristen Galfetti, 617-498-3362

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Optimization of alloy materials: Diffusion processes in nano particles decoded November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

European Commission Project Creates Pilot Line for Companies to Develop Mid-Infrared Devices: Companies Can Submit Proposals for Possible Matching Funds To Help Develop Prototypes November 13th, 2018

Nanomedicine

Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018 November 9th, 2018

Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018 November 9th, 2018

WSU researchers develop new technique to understand biology at the nanoscale November 7th, 2018

A record-long polymer DNA negative November 6th, 2018

Announcements

Optimization of alloy materials: Diffusion processes in nano particles decoded November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

European Commission Project Creates Pilot Line for Companies to Develop Mid-Infrared Devices: Companies Can Submit Proposals for Possible Matching Funds To Help Develop Prototypes November 13th, 2018

Appointments/Promotions/New hires/Resignations/Deaths

Jim Barnhart Joins Nanometrics as Senior Vice President of Operations March 15th, 2018

Jonathan Chou to Join Nanometrics as Chief Financial Officer February 26th, 2018

Ocean Optics Grows Sales Organization with Executive Appointments: Henry Langston promoted, Christine Stannard joins spectral sensing product developer December 23rd, 2017

Emmanuel Sabonnadiere is Leti’s New CEO November 28th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project